

**Ind-Swift Laboratories Limited***Registered Office*SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026**Date: 29th October, 2026****The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001****The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051****BSE Scrip Code: 532305****NSE Symbol: INDSWFTLAB****SUB: OUTCOME OF BOARD MEETING**

Dear Sir/Ma'am,

Pursuant to Regulation 30, Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform that the Board of Directors of the Company, at its meeting held today, i.e., Thursday, October 29, 2026, has, inter alia, considered and approved the following:

- I.** Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter and six months ended September 30, 2026, along with the Limited Review Reports issued by the Statutory Auditors.

A copy of the Financial Results together with the Limited Review Reports is enclosed herewith as **Annexure I**.

The said financial results shall also be made available on the Company's website at www.indswiftgroup.com/investor.

The Board Meeting commenced at 12:00 P.M and concluded at 02:45 P.M.

You are requested to kindly take the same on record.

Thanking you,

For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP
VERMA**

Digitally signed by
PARDEEP VERMA
Date: 2026.10.29 14:57:03
+05'30'



**PARDEEP VERMA
VP – CORPORATE AFFAIRS &
COMPANY SECRETARY**

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Ind-Swift Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

Review Report to
The Board of Directors
Ind-Swift Laboratories Ltd

1. We have reviewed the accompanying statement of unaudited standalone financial results (the "Statement") of Ind-Swift Laboratories Ltd. (the "Company") for the Quarter ended September 30, 2026, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rattan Kaur & Associates
Chartered Accountants
(Regd No: 022513N)


Rattan Kaur
Partner
M. No. 513530

Place: Chandigarh

Date: 29-10-2026

UDIN: 26513530ERC/SN2558

IND SWIFT LABORATORIES LTD.

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPT 2026

CIN L24232CH1995PLC015553

	Rs. In Lakhs					
	STANDALONE					
Particulars	Quarter Ended 30.09.2026	Quarter Ended 30.06.2026	Quarter Ended 30.09.2025	Half Year Ended 30.09.2026	Half Year Ended 30.09.2025	Year Ended 31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	23489.04	18608.24	15643.33	42097.28	31001.65	63588.85
Other Income	759.87	762.82	1186.31	1522.69	2085.63	4695.52
Total Income	24248.91	19371.06	16829.63	43619.97	33087.28	68284.37
EXPENSES:						
a Cost of Materials Consumed	9286.19	8172.64	6591.08	17458.83	13035.77	27474.17
b. Purchase of stock in Trade	1605.40	1326.79	1189.40	2932.19	2055.63	3765.84
c.(Increase) /decrease in FG,WIP & stock in trade	(287.26)	(1978.22)	(56.55)	(2265.49)	(241.21)	(2890.74)
d. Employee benefit	3736.21	3895.35	3572.76	7631.55	6773.24	13632.80
e. Finance Costs	133.31	70.51	201.46	203.83	316.59	140.40
f. Depreciation	777.09	758.31	697.75	1535.39	1365.42	3056.69
g. Other expenditure	4915.76	3859.33	3528.05	8775.09	7693.62	16982.90
TOTAL EXPENSES	20166.70	16104.71	15723.94	36271.41	30999.07	62162.06
Profit(loss) before exceptional Items and Tax	4082.21	3266.35	1105.69	7348.56	2088.21	6122.31
Exceptional Items (Income) /loss	57.97	23.58	0.00	81.55	0.00	1100.64
Profit(loss) before Tax (After exceptional items)	4024.23	3242.77	1105.69	7267.00	2088.21	5021.67
Tax Expenses :-						
Current Tax	921.41	798.37	230.00	1719.78	400.58	1306.14
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(540.15)
Profit/ (Loss) after tax and before share of	3102.82	2444.40	875.69	5547.22	1687.63	4255.68
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	3102.82	2444.40	875.69	5547.22	1687.63	4255.68
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit /(Loss) for the period after tax & Exceptional items)	3102.82	2444.40	875.69	5547.22	1687.63	4255.68
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	87.45
B) Items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	0.00	0.00	0.00	87.45
Total Comprehensive Income for the Period	3102.82	2444.40	875.69	5547.22	1687.63	4168.23
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	8696.16	8696.16	8161.16	8696.16	8161.16	8683.66
Reserve excluding revaluation reserves						137069.72
EPS (of Rs. 10/- each) (Not annualised)						
Basic	3.57	2.81	1.09	6.38	2.11	5.09
Diluted	3.56	2.81	1.05	6.36	2.02	4.97

For Ind Swift Laboratories Ltd.

N R MUNJAL
Chairman



Date : 29-10-2026
Place : Chandigarh

Regd. Office: SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101, INDIA

0172-2730503, 2730920, 5061851-53 info@indswiftlabs.com www.indswiftgroup.com

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

CIN No. L24232CH1995PLC015553

Follow us: f in x y t



IND-SWIFT LABORATORIES LIMITED

Standalone Statement of Assets & Liabilities :

CIN: L24232CH1995PLC015553

PARTICULARS	As at 30.09.2026 (Rs. in Lakhs)	As at 31.03.2026 (Rs. in Lakhs)
ASSETS		
Non-current assets :		
Property, Plant and Equipment	27,353.96	27,514.10
Capital work-in Progress	3,978.64	1,020.22
Right of Use-Assets	117.07	117.94
Investment property	220.17	220.74
Other Intangible assets	3,489.48	2,524.59
Intangible Assets under Development	203.43	220.95
Financial Assets		
a) Investments	32,391.97	31,854.55
b) Loans	7,354.40	7,354.40
c) Others	216.69	264.58
Deferred tax assets (net)	5,033.70	5,033.70
Other Non-current assets	3,238.70	1,817.58
TOTAL NON-CURRENT ASSETS	83,598.21	77,943.35
Current Assets		
Inventories	16,835.17	14,297.60
Financial Assets		
(i) Investments	4,502.84	1,190.15
(ii) Trade receivables	23,478.52	18,876.90
(iii) Cash and Cash Equivalents	32,281.43	41,499.12
(iv) Other financial assets	3,369.89	3,010.59
Other current assets	11,362.45	8,616.44
TOTAL CURRENT ASSETS	91,830.30	87,490.81
TOTAL ASSETS	1,75,428.51	1,65,434.16
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	8,696.16	8,683.66
(b) Other Equity	1,37,362.49	1,28,386.06
TOTAL EQUITY	1,46,058.65	1,37,069.72
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	1,514.45	1,210.78
(b) Lease Liabilities	19.51	19.51
Provisions	1,356.19	1,305.01
Other Non current Liabilities	576.56	674.55
TOTAL NON- CURRENT LIABILITIES	3,466.71	3,209.85
Current liabilities		
Financial Liabilities		
(i) Borrowings	433.91	559.36
(ii) Lease Liabilities	1.54	1.54
(iii) Trade payables		
- total outstanding dues of micro and small enterprises; and	80.89	977.39
- total outstanding dues of creditors other than micro and	13,288.85	13,423.23
(iv) Other Financial Liabilities		
(a) Borrowings	159.67	258.94
Other current liabilities	11,040.56	9,656.17
Provisions	277.96	277.96
Current Tax Liabilities (net)	619.78	-
TOTAL CURRENT LIABILITIES	25,903.15	25,154.59
TOTAL LIABILITIES	29,369.87	28,364.44
TOTAL EQUITY AND LIABILITIES	1,75,428.51	1,65,434.16

For Ind Swift Laboratories Ltd.

Naurat
N R MUNJAL
Chairman



Date : 29-10-2026
Place : Chandigarh



IND-SWIFT LABORATORIES LIMITED
STANDALONE CASH FLOW STATEMENT FOR YEAR ENDED 30.09.2026

	Year ended 30.09.2026 Rs in Lakhs	Year ended 31.03.2026 Rs in Lakhs
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Exceptional Items	7,348.56	6,122.31
ADJUSTMENTS FOR:		
i) Depreciation, Amortisation and Impairment Expenses	1,535.39	3,056.69
ii) Doubtful Trade Receivables/Advance Provided	-	(145.72)
iii) Finance Costs	9.03	19.36
iv) Interest received	(1,454.33)	(5,548.24)
v) Loss/(Profit) on sale of Property, Plant and Equipment/Intangible Assets	-	17.28
vi) Loss/(Profit) on Investments	(12.69)	746.45
vii) Amortisation of Subsidy	(0.79)	(1.58)
viii) Unrealised Foreign Exchange on Debtors	553.48	(471.16)
ix) Unrealised Foreign Exchange on Creditors	(5.29)	(8.19)
x) ESOP	-	184.95
xi) Provision for Leave Encashment/Gratuity	51.18	157.12
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	8,024.54	4,129.27
CHANGES IN WORKING CAPITAL:		
i) Trade & Other Receivables	(5,236.66)	(3,483.43)
ii) Inventories	(2,537.57)	(3,572.67)
iii) Other assets	(3,068.50)	(4,907.03)
iv) Current Liabilities	358.80	4,484.55
Cash Generated from Operations	(2,459.40)	(3,349.31)
Net income tax paid	(1,088.92)	(670.06)
Net Cash flow from operating Activities	(3,548.32)	(4,019.37)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(i) Payment for Acquisition of Property, Plant and Equipment/Intangible Assets (including CWIP and Intangible Assets, Intangible Assets under Development, Capital Advances & Capital Creditors)	(6,700.72)	(8,772.13)
ii) Proceeds on sale of Property, Plant and Equipment/Intangible Assets		118.99
iii) (Purchase)/ Sale of Investments	(3,837.42)	(6,911.24)
iv) Interest Received	1,454.33	5,548.24
Net Cash from investing activities	(9,083.80)	(10,016.14)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Borrowings	178.22	(1,162.02)
ii) Finance Cost paid	(108.30)	(547.73)
iii) Proceeds from Fully Convertible Warrants & Issue of Equity Shares	3,429.21	16,297.84
iv) Proceeds from ESOP	12.50	12.50
v) Increase/Decrease in Security Deposit	(97.98)	(74.60)
Net Cash flow from Financing Activities	3,413.64	14,525.99
Net increase in Cash or Cash Equivalents	(9,218.49)	490.48
Opening Cash & Cash Equivalents	41,499.12	41,008.66
Closing Cash & Cash Equivalents	32,280.63	41,499.13

For Ind Swift Laboratories Ltd.

N R Munjal
N R MUNJAL
Chairman

Date : 29-10-2026
Place : Chandigarh



Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of Ind-Swift Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

**Review Report to
The Board of Directors
Ind-Swift Laboratories Ltd**

1) We have reviewed the accompanying statement of unaudited consolidated financial results (the "Statement") of Ind-Swift Laboratories Ltd. (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "The Group"), its Joint Ventures for the Quarter ended September 30, 2026, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2) The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.



4) The Statement includes the results of the following entities:

Subsidiaries

- Fortune (India) Constructions Ltd.
- MJM Remedies Private Limited
- Ind Swift Laboratories Inc. USA
- ISLL Middle East LLC-FZ
- Ind-Swift India Ltd (Kenya)

Joint Venture

- Indis Healthcare LLP
- Capital Strikers LLP

5) Based on our review conducted and procedures performed as stated in Paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) The accompanying Statement includes unaudited interim financial results and other financial information in respect of:

- 2 subsidiaries, whose unaudited interim financial results and other financial information include total revenue of Rs. 76.05 Lakhs, total net loss before tax of Rs. 9.22 Lakhs, total comprehensive loss of Rs. 9.22 Lakhs, for the quarter ended September 30, 2026 as considered in the Statement whose financial information has not been reviewed by their auditors. The unaudited interim financial results and other financial information of these subsidiaries have been approved and furnished to us by the Holding Company's Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other financial information. According to the information and explanations given to us by Management, these unaudited interim financial results and other financial information are not material to the Group.
- 3 subsidiaries, whose unaudited interim financial results and other financial information include total revenue of Rs. 923.82 Lakhs, total net profit before tax of Rs. 765.24 Lakhs and total comprehensive income of Rs. 1051.31 Lakhs for the quarter ended September 30, 2026. The unaudited interim financial results and other financial information of these subsidiaries have been prepared in accordance with accounting principles generally accepted in their respective countries for statutory purposes and have not been reviewed by their auditors. The Holding Company's management has converted the financial statements of such subsidiaries located outside India from



accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. According to the information and explanations given to us by Holding Company's Management, these unaudited interim financial results and other financial information are not material to the Group. We have not reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based solely the conversion adjustments prepared by the management of the Holding Company.

- 2 Joint Ventures, whose unaudited interim financial results and other financial information includes the Group's share of net profit before taxes of Rs. 7.19 Lakhs, for the quarter ended September 30, 2026 respectively. These unaudited interim financial results and other financial information have been approved and furnished to us by Holding Company's management and our conclusion on the Statement, in so far as it relates to the affairs included in respect of these Joint Ventures, is based solely on such unaudited financial statements and other financial information. According to the information and explanations given to us by the Holding Company's Management, these unaudited interim financial results and other financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For Rattan Kaur & Associates
Chartered Accountants
(Regd No: 022513N)



Rattan Kaur
Partner
M. No. 513530

Place: Chandigarh

Date: 29-10-2026

UDIN: 26513530 SUS KLJ4241

IND SWIFT LABORATORIES LTD.

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPT 2026

CIN L24232CH1995PLC015553

	Rs. In Lakhs					
	CONSOLIDATED					
Particulars	Quarter Ended 30.09.2026	Quarter Ended 30.06.2026	Quarter Ended 30.09.2025	Half Year Ended 30.09.2026	Half Year Ended 30.09.2025	Year Ended 31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	24046.35	19145.39	15864.01	43191.75	31696.26	64913.61
Other Income	759.93	765.20	1186.39	1525.13	2085.71	4696.72
Total Income	24806.28	19910.59	17050.40	44716.87	33781.97	69610.33
EXPENSES:						
a Cost of Materials Consumed	9287.09	8175.83	6610.32	17462.92	13150.27	27680.30
b. Purchase of stock in Trade	1614.44	1350.38	1189.40	2964.82	2055.63	3816.13
c.(Increase) /decrease in FG,WIP & stock in trade	(249.91)	(1692.87)	(34.71)	(1942.78)	(132.03)	(2693.47)
d. Employee benefit	3797.05	3956.06	3627.06	7753.10	6880.19	13853.41
e. Finance Costs	133.33	70.52	201.46	203.85	316.60	140.49
f. Depreciation	777.09	758.31	697.75	1535.39	1365.42	3060.59
g. Other expenditure	5051.48	4012.63	3724.81	9064.11	8076.16	17576.57
TOTAL EXPENSES	20410.56	16630.85	16016.09	37041.41	31712.24	63434.02
Profit(loss) before exceptional Items and Tax	4395.73	3279.74	1034.31	7675.47	2069.72	6176.31
Exceptional Items (Income) /loss	57.97	23.58	0.00	81.55	0.00	1100.64
Profit(loss) before Tax (After exceptional Items)	4337.75	3256.16	1034.31	7593.91	2069.72	5075.66
Tax Expenses :-						
Current Tax	922.68	799.92	230.00	1722.60	400.58	1313.11
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	(0.78)	0.00	(0.78)	0.00	(540.15)
Profit/ (Loss) after tax and before share of	3415.07	2457.02	804.31	5872.09	1669.14	4302.71
Share of profit (loss) in joint venture	7.19	11.40	(5.29)	18.59	7.34	9.77
Profit (+)/ Loss (-) for the period from continuing operations	3422.25	2468.42	799.03	5890.68	1676.48	4312.48
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit /(Loss) for the period after tax & Exceptional Items)	3422.25	2468.42	799.03	5890.68	1676.48	4312.48
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	87.45
B) Items that will be reclassified into P/L A/c	(287.35)	(8.23)	0.00	(295.58)	0.00	377.89
Other Comprehensive Income (Loss) for the period , net of Tax	(287.35)	(8.23)	0.00	(295.58)	0.00	465.34
Total Comprehensive Income for the Period	3709.60	2476.66	799.03	6186.26	1676.48	3847.14
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	8696.16	8696.16	8161.16	8696.16	8161.16	8683.66
Reserve excluding revaluation reserves						138402.35
EPS (of Rs. 10/- each) (Not annualised)						
Basic	3.94	2.84	1.00	6.77	2.09	5.16
Diluted	3.92	2.84	0.96	6.75	2.01	5.03

For Ind Swift Laboratories Ltd.

N R MUNJAL
Chairman



Date : 29-10-2026
Place : Chandigarh

Regd. Office: SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101, INDIA

CIN No. L24232CH1995PLC015553

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com





Ind-Swift
LABORATORIES LIMITED

One World One Health One Ind-Swift

IND-SWIFT LABORATORIES LIMITED

Consolidated Statement of Assets & Liabilities :

CIN: L24232CH1995PLC015553

PARTICULARS	As at 30.09.2026	As at 31.03.2026
	Rs. in Lakhs	Rs. in Lakhs
ASSETS		
1. Non-current assets :		
Property, Plant and Equipment	27,353.96	27,514.10
Capital work-in progress	3,978.64	1,020.22
Right of Use-Assets	117.07	117.94
Investment property	220.17	220.74
Other Intangible assets	3,489.48	2,524.59
Intangible Assets under Development	203.43	220.95
Financial Assets		
a) Investments	23,633.72	23,562.47
b) Loans	7,354.40	7,354.40
(c) Other	222.96	272.33
Deferred tax assets (net)	5,035.18	5,034.39
Other non-current assets	3,238.70	1,817.58
TOTAL NON- CURRENT ASSETS	74,847.71	69,659.71
2. Current Assets		
(a) Inventories	17,007.90	14,793.03
(b) Financial Assets		
(i) Investments	4,502.84	1,190.15
(ii) Trade receivables	24,507.10	19,854.58
(iii) Cash and cash equivalents	34,035.47	42,984.86
(iv) Other financial assets	3,369.89	3,010.59
Other current assets	18,850.84	15,842.04
Total Current Assets	1,02,274.04	97,675.26
Total Assets	1,77,121.75	1,67,334.98
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share capital	8,696.16	8,683.66
(b) Other Equity	1,38,742.35	1,29,718.69
Equity attributable to equity holders of the Company	1,47,438.50	1,38,402.35
(c) Non-Controlling interest	(5.10)	(5.75)
Total Equity	1,47,433.41	1,38,396.60
LIABILITIES		
1. Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,521.20	1,210.78
(ii) Lease Liabilities	19.51	19.51
Provisions	1,356.19	1,305.01
(c) Other Non current Liabilities	576.56	674.55
Total Non-Current Liabilities	3,473.46	3,209.85
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	433.91	559.36
(ii) Lease Liabilities	1.54	1.54
(iii) Trade payables		
- total outstanding dues to micro and small enterprises; and	80.89	977.39
- total outstanding dues of creditors other than micro and	13,471.15	13,608.58
Other Financial Liabilities		
(a) Borrowings	159.67	258.94
Other current liabilities	11,160.08	10,037.71
Provision	277.96	277.96
Current Tax Liabilities (net)	629.68	7.04
Total Current Liabilities	26,214.88	25,728.53
Total LIABILITIES	29,688.34	28,938.38
TOTAL EQUITY AND LIABILITIES	1,77,121.75	1,67,334.98

For Ind Swift Laboratories Ltd.

N R Munjal

N R MUNJAL
Chairman

Date : 29-10-2026
Place : Chandigarh

Regd. Office: SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101, INDIA

CIN No: L24232CH1995PLC015553

☎ 0172-2730503, 2730920, 5061851-53

✉ info@indswiftlabs.com

🌐 www.indswiftgroup.com

Follow us:     

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com



IND-SWIFT LABORATORIES LIMITED
CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30.09.2026

	Year ended 30.09.2026	Year ended 31.03.2026
	Rs in Lakhs	
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Exceptional Items	7,675.47	6,176.32
ADJUSTMENTS FOR:		
i) Depreciation, Amortisation and Impairment Expenses	1,535.39	3,060.59
ii) Doubtful Trade Receivables/Advance Provided	-	(142.02)
iii) Finance Costs	16.03	19.36
iv) Interest received	(1,456.71)	(5,549.16)
v) Loss/(Profit) on sale of Property, Plant and Equipment/Intangible Assets	-	17.28
vi) Loss/(Profit) on Investments	(12.69)	746.45
vii) Amortisation of Subsidy	(0.79)	(1.58)
viii) Unrealised Foreign Exchange on Debtors	553.48	(471.16)
ix) Unrealised Foreign Exchange on Creditors	(5.29)	(8.19)
x) ESOP	-	184.95
xi) Provision for Leave Encashment/Gratuity	51.18	157.12
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	8,356.07	4,189.95
CHANGES IN WORKING CAPITAL:		
i) Trade & Other Receivables	(5,287.55)	(4,031.88)
ii) Inventories	(2,214.87)	(3,375.40)
iii) Other assets	(3,329.75)	(7,599.24)
iv) Current Liabilities	93.72	4,669.78
Cash Generated from Operations	(2,382.36)	(6,146.79)
Net income tax paid	(1,088.95)	(670.06)
Net Cash flow from operating Activities	(3,471.31)	(6,816.85)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(i) Payment for Acquisition of Property, Plant and Equipment/Intangible Assets (including CWIP and Intangible Assets, Intangible Assets under Development, Capital Advances & Capital Creditors	(6,700.72)	(8,772.13)
ii) Proceeds on sale of Property, Plant and Equipment/Intangible Assets		118.99
iii) (Purchase)/ Sale of Investments	(3,352.67)	(4,164.34)
iv) Interest Received	1,456.71	5,549.16
Net Cash from investing activities	(8,596.68)	(7,268.32)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Borrowings	184.97	(1,507.14)
ii) Finance Cost paid	(115.30)	(547.73)
iii) Proceeds from Fully Convertible Warrants & Issue of Equity Shares	3,429.21	16,297.84
iv) Proceeds from ESOP	12.50	12.50
v) Increase/Decrease in Security Deposit	(97.98)	(74.60)
Net Cash flow from Financing Activities	3,413.39	14,180.86
Net increase in Cash or Cash Equivalents	(8,654.60)	95.69
Opening Cash & Cash Equivalents	42,984.86	42,511.29
Add; unrealised Gain/(loss) in FCTR	(295.58)	377.89
Closing Cash & Cash Equivalents	34,034.68	42,984.87

For Ind Swift Laboratories Ltd.

N R MUNJAL
Chairman

Date : 29-10-2026
Place : Chandigarh



Notes: -

1. During the quarter ended 30th September, 2026, the company has achieved an EBITDA of Rs. 42.33 Crores and earned a Standalone Net Profit of Rs. 31.03 Crores as compared to the EBITDA of Rs. 8.55 Crores and Standalone Net Profit of Rs. 8.76 Crores during the corresponding quarter of previous financial year.
2. The above Un-Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 29th October, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
3. The Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30.09.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
4. The figures for the quarter ended March 31, 2026 were the balancing figures between audited figures in respect of full financial year and the year-to-date figures upto the third quarter of the previous financial year.
5. Exceptional items for the quarter ended 30th September, 2026 is Rs. 57.97 Lakhs whereas for 30th June, 2026 comprise of Rs. 23.58 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable.
6. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.
7. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
 - a) Ind-Swift Laboratories Inc., USA (Subsidiary)
 - b) Fortune (India) Constructions Limited (Subsidiary)
 - c) Indis Healthcare LLP (Joint Venture)
 - d) MJM Rcmedics Private Limited (Subsidiary)
 - e) ISLL Middle East LLC-FZ (Subsidiary)
 - f) Ind Swift India Limited Kenya (Subsidiary)
 - g) Capital Strikers LLP (Joint Venture)

Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'



8. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end.
9. During the quarter under review the Company has not issued any Non-Convertible Debt Securities.
10. The previous period figures have been re-grouped and re-classified wherever necessary.
11. The Company is exclusively in the Pharmaceutical Business segment.

For Ind-Swift Laboratories Limited



Navrattan Munjal
Chairman

Place: Chandigarh
Date: 29th October, 2026

